These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 28617895)

  • 41. Detectable Viremia at the End of Treatment With Direct-Acting Antivirals Can Be Associated With Subsequent Clinical Cure in Patients With Chronic Hepatitis C: A Case Series.
    Childs-Kean LM; Hong J
    Gastroenterology; 2017 Oct; 153(4):1165-1166. PubMed ID: 28881195
    [No Abstract]   [Full Text] [Related]  

  • 42. Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals.
    Akuta N; Kobayashi M; Suzuki F; Sezaki H; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
    Oncology; 2016; 91(6):341-347. PubMed ID: 27694754
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Succesful treatment of chronic hepatitis C virus infection with daclatasvir and asunaprevir in a transfusion dependent thalassaemia patient.
    Köklü H; Köklü S; Ozturk O; Aksoy EK; Tseveldorj N
    Acta Gastroenterol Belg; 2016; 79(4):501-502. PubMed ID: 28209112
    [No Abstract]   [Full Text] [Related]  

  • 44. Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients.
    Everson GT; Sims KD; Thuluvath PJ; Lawitz E; Hassanein T; Rodriguez-Torres M; Desta T; Hawkins T; Levin JM; Hinestrosa F; Rustgi V; Schwartz H; Younossi Z; Webster L; Gitlin N; Eley T; Huang SP; McPhee F; Grasela DM; Gardiner DF
    Liver Int; 2016 Feb; 36(2):189-97. PubMed ID: 26473667
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Modeling population heterogeneity in viral dynamics for chronic hepatitis C infection: Insights from Phase 3 telaprevir clinical studies.
    Haseltine EL; Kimko H; Luo H; Tolsma J; Bartels DJ; Kieffer TL; Garg V
    J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):681-98. PubMed ID: 26289844
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Timing of Hepatitis C Antiviral Therapy in Liver Transplant Recipients With Direct-acting Agents.
    Suraweera D; Saab EG; Tong MJ; Saab S
    Exp Clin Transplant; 2016 Jun; 14(3):243-51. PubMed ID: 27221717
    [TBL] [Abstract][Full Text] [Related]  

  • 47. On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir.
    Kowdley KV; Nelson DR; Lalezari JP; Box T; Gitlin N; Poleynard G; Rabinovitz M; Ravendhran N; Sheikh AM; Siddique A; Bhore R; Noviello S; Rana K
    Liver Int; 2016 Nov; 36(11):1611-1618. PubMed ID: 27188960
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis.
    Toyoda H; Kumada T; Tada T; Takaguchi K; Ishikawa T; Tsuji K; Zeniya M; Iio E; Tanaka Y
    J Gastroenterol; 2016 Jul; 51(7):741-7. PubMed ID: 26872889
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Incidence and predictors of direct-acting antiviral treatment failure in Turkish patients with chronic hepatitis C genotype 1b infection.
    Cabalak M; Bal T; Onlen Y; Demir M
    Trop Doct; 2020 Apr; 50(2):141-146. PubMed ID: 31810415
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hepatitis C virus genotype 4-infection and interferon-free treatment in Egypt.
    Kanda T; Matsuoka S; Moriyama M
    Hepatol Int; 2018 Jul; 12(4):291-293. PubMed ID: 29992512
    [No Abstract]   [Full Text] [Related]  

  • 51. Drug-induced lung injury associated with combination therapy of daclatasvir and asunaprevir: The first case report.
    Kamada T; Furuta K; Tomioka H
    Respir Investig; 2016 May; 54(3):207-10. PubMed ID: 27108017
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cytolytic hepatitis related to simeprevir overdose in a patient with cirrhosis and HIV-HCV genotype 1 coinfection.
    Lison H; Garioud A; Halfon P; Jambon S; Cordier F; Verbrigghe C; Landgraf N; Pitre C; Nguyen-Khac E; Cadranel JF
    Eur J Gastroenterol Hepatol; 2016 Apr; 28(4):486-7. PubMed ID: 26934415
    [No Abstract]   [Full Text] [Related]  

  • 53. Short article: Viral dynamics among hepatitis C virus chronic infected patients during direct-acting antiviral agents therapy: impact for monitoring and optimizing treatment duration.
    Tabernilla A; Grandal M; Pernas B; Castro-Iglesias A; Rodríguez-Osorio I; Mena A; Delgado M; Cid P; Pedreira JD; Poveda E
    Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):781-785. PubMed ID: 28410351
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Preliminary study of two antiviral agents for hepatitis C genotype 1.
    Lok AS; Gardiner DF; Lawitz E; Martorell C; Everson GT; Ghalib R; Reindollar R; Rustgi V; McPhee F; Wind-Rotolo M; Persson A; Zhu K; Dimitrova DI; Eley T; Guo T; Grasela DM; Pasquinelli C
    N Engl J Med; 2012 Jan; 366(3):216-24. PubMed ID: 22256805
    [TBL] [Abstract][Full Text] [Related]  

  • 55. "There are decades where nothing happens; and there are weeks where decades happen"--Vladimir Ilyich Lenin.
    Friedman SL
    J Hepatol; 2014 Mar; 60(3):471-2. PubMed ID: 24333649
    [No Abstract]   [Full Text] [Related]  

  • 56. Simeprevir for the treatment of chronic hepatitis C genotype 1 infection.
    Takehara T
    Expert Rev Anti Infect Ther; 2014 Aug; 12(8):909-17. PubMed ID: 24882512
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hepatitis C: How Good Are Real-Life Data and Do Generics Work.
    Tran AN; Lim JK
    Gastroenterol Clin North Am; 2020 Jun; 49(2):279-299. PubMed ID: 32389363
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Asunaprevir plus daclatasvir for the treatment of chronic hepatitis C virus infection.
    Zeuli JD; Adie SK; Rizza SA; Temesgen Z
    Drugs Today (Barc); 2015 Nov; 51(11):629-43. PubMed ID: 26744738
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study.
    Dalgard O; Weiland O; Noraberg G; Karlsen L; Heggelund L; Färkkilâ M; Balslev U; Belard E; Øvrehus A; Skalshøi Kjær M; Krarup H; Thorup Røge B; Hallager S; Madsen LG; Lund Laursen A; Lagging M; Weis N
    PLoS One; 2017; 12(7):e0179764. PubMed ID: 28704381
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sofosbuvir and velpatasvir for the treatment of hepatitis C.
    Jackson WE; Everson GT
    Expert Rev Gastroenterol Hepatol; 2017 Jun; 11(6):501-505. PubMed ID: 28468532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.